Treace Medical Concepts (TMCI) Net Income towards Common Stockholders (2020 - 2026)
Treace Medical Concepts' (TMCI) quarterly Net Income towards Common Stockholders came in at -$20.8 million in Q1 2026, down 29.87% YoY from -$29.7 million in Q1 2025, and down 199.47% on a QoQ basis from -$7.0 million in Q4 2025.
Treace Medical Concepts (TMCI) Net Income towards Common Stockholders (2020 - 2026) Analysis & Trends
Treace Medical Concepts (TMCI) has 7 years of Net Income towards Common Stockholders data on file, last reported at -$20.8 million in Q1 2026.
- Quarterly Net Income towards Common Stockholders fell 29.87% year-over-year to -$20.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$61.7 million (down 15.08% YoY) and the FY2025 annual result came in at -$108.0 million, down 13.84% from the prior year.
- Net Income towards Common Stockholders declined to -$20.8 million in Q1 2026, from -$7.0 million in the prior quarter.
- In the past five years, Net Income towards Common Stockholders ranged from a high of -$873000.0 in Q4 2024 to a low of -$21.3 million in Q2 2024.
- A 5-year average of -$13.3 million and a median of -$15.4 million in 2024 frame the typical range for Net Income towards Common Stockholders.
- Annual changes were most pronounced in 2024 — Net Income towards Common Stockholders soared 86.31% — and 2025, when it sank 697.37%.
- Tracing TMCI's Net Income towards Common Stockholders over 5 years: stood at -$4.4 million in 2022, then slumped by 44.54% to -$6.4 million in 2023, then soared by 86.31% to -$873000.0 in 2024, then slumped by 697.37% to -$7.0 million in 2025, then plunged by 199.47% to -$20.8 million in 2026.
- The last three Net Income towards Common Stockholders figures came in at -$20.8 million (Q1 2026), -$7.0 million (Q4 2025), and -$16.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 198.70 Bn | 193.10 Bn | 7.27 Bn | 928.00 Mn |
| 2 | Stryker | 125.85 Bn | 122.37 Bn | 4.50 Bn | 1.28 Bn |
| 3 | Medtronic | 118.44 Bn | 109.22 Bn | 6.41 Bn | 1.26 Bn |
| 4 | Boston Scientific | 72.64 Bn | 72.10 Bn | 3.85 Bn | 907.00 Mn |
| 5 | Edwards Lifesciences | 51.94 Bn | 47.69 Bn | 1.35 Bn | 241.40 Mn |
| 6 | Dexcom | 34.48 Bn | 32.53 Bn | 830.00 Mn | 249.10 Mn |
| 7 | GE HealthCare Technologies | 33.60 Bn | 31.49 Bn | 2.18 Bn | 574.00 Mn |
| 8 | Koninklijke Philips | 26.30 Bn | 22.98 Bn | 4.55 Bn | 621.86 Mn |
| 9 | Steris | 23.00 Bn | 22.52 Bn | 684.20 Mn | 201.00 Mn |
| 10 | Treace Medical Concepts | 290.12 Mn | 244.50 Mn | 35.61 Mn | -16.08 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -18.47 Mn |
| Mar 31, 2026 | -20.85 Mn |
| Dec 31, 2025 | -6.96 Mn |
| Sep 30, 2025 | -16.38 Mn |
| Jun 30, 2025 | -17.52 Mn |
| Mar 31, 2025 | -16.05 Mn |
| Dec 31, 2024 | -873,000.00 |
| Sep 30, 2024 | -15.38 Mn |
| Jun 30, 2024 | -21.32 Mn |
| Mar 31, 2024 | -18.75 Mn |
| Dec 31, 2023 | -6.38 Mn |
| Sep 30, 2023 | -17.54 Mn |
| Jun 30, 2023 | -12.37 Mn |
| Mar 31, 2023 | -13.58 Mn |
| Dec 31, 2022 | -4.41 Mn |
| Sep 30, 2022 | -12.13 Mn |
| Jun 30, 2022 | -17.23 Mn |
| Mar 31, 2022 | -9.04 Mn |
| Dec 31, 2021 | -6.62 Mn |
| Sep 30, 2021 | -6.42 Mn |